GlassScriptPhysician profile
Eric P Velazquez
NPI 1518385111
$2,622.39
in general payments reported to CMS, 2019-2025
25 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.75 · 2021: $205 · 2022: $452 · 2023: $396 · 2024: $1,152 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921 · Education: $20.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.76 |
| Education | $20.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $315.97 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novo Nordisk INC | $259.16 | 2021-2025 | Sogroya |
| Abbvie INC. | $233.86 | 2020-2024 | Lupron Depot |
| Ascendis Pharma Endocrinology INC | $207.31 | 2022-2025 | Skytrofa |
| Sanofi-Aventis U.S. LLC | $186.74 | 2023-2025 | |
| Medtronic, INC. | $186.10 | 2021-2024 | Minimed 780g |
| Tolmar, INC. | $185.93 | 2024-2025 | Fensolvi |
| Insulet Corporation | $178.59 | 2021-2024 | Omnipod |
| Pfizer INC. | $138.82 | 2022-2024 | |
| Dexcom, INC. | $112.20 | 2021-2025 | Dexcom G6 Transmitter |
| Rhythm Pharmaceuticals, INC. | $98.47 | 2022-2025 | Imcivree, Imcivree |
| Eton Pharmaceuticals, INC. | $80.78 | 2023-2025 | Alkindi, Increlex, Khindivi |
| Azurity Pharmaceuticals, INC. | $67.98 | 2023-2024 | Triptodur, Triptodur |
| Lilly USA, LLC | $56.16 | 2021-2023 | Baqsimi |
| Sequel Med Tech, LLC | $54.05 | 2025 | Twiist |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $44.02 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $38.90 | 2021-2022 | |
| Ibsa Pharma INC. | $27.70 | 2021-2024 | Tirosint, Licart |
| Alexion Pharmaceuticals, INC. | $24.85 | 2024 | Strensiq |
| Endo Pharmaceuticals INC. | $24.31 | 2023 | Supprelin |
| Endo USA, INC. | $23.92 | 2024 | Supprelin |
| Neurocrine Biosciences, INC. | $20.44 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $19.40 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.93 | 2021 | |
| Biomarin Pharmaceutical INC. | $17.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Velazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.